Coronavirus immunization turn out expected in under 3 months in UK: The Times Kumar Jeetendra | October 3, 2020 A mass roll-out of a COVID-19 vaccine in Britain could be completed in as little as three months, the Times reported, citing government scientists. Scientists working on the Oxford vaccine hope regulators approve it before the beginning of 2021, the paper said. A complete COVID-19 immunization programme, which would exclude children, could be faster than …
Role of Aerogen Nebulization in High Flow Oxygen Therapy Kumar Jeetendra | October 2, 2020 High flow oxygen therapy is a form of respiratory support used in the hospital where oxygen, often in conjunction with compressed air and humidification, is delivered to a patient at rates of flow higher than that delivered traditionally in oxygen therapy. High flow oxygen therapy is intended to Eliminate most of the anatomic dead space …
AstraZeneca resumes COVID-19 immunization preliminary in Japan, US still stopped Kumar Jeetendra | October 2, 2020 AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 vaccine declared in Japan, while adding that it was in talks with regulators on data necessary to restart studies in the United States, where they remain halted. Several global trials of the vaccine, AZD1222, were put on hold last month after an unexplained illness …
Russia to start Phase III preliminaries of second COVID-19 antibody in November-December: Report Kumar Jeetendra | October 2, 2020 Russia begins Phase III trials of a second possible vaccine against COVID-19, developed by Siberia’s Vector Institute, in November-December, the TASS news agency cited Russian consumer security watchdog Rospotrebnadzor as saying on October 2. Early-stage clinical trials for the vaccine have been completed on Wednesday.
Researchers distinguish interesting examples in COVID-19 transmission in India Kumar Jeetendra | October 1, 2020 Researchers, including those from the Government of Tamil Nadu, and Andhra Pradesh, have conducted one of the largest analysis of COVID-19 epidemiology to date, and have discovered that both cases and deaths due to the disease are more heavily concentrated in the 40-69 year age group in India than is seen in high-income nations, among …
Moderna COVID-19 antibody seems safe, gives indications of working in more seasoned grown-ups: Study Kumar Jeetendra | September 30, 2020 Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those found in younger adults, with side effects about on par with high-dose flu shots, researchers said on Tuesday. The study, published in the New England Journal of Medicine, offers …
Russia finishes clinical preliminaries of second potential COVID-19 immunization Kumar Jeetendra | September 30, 2020 Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, the RIA news agency mentioned Russian customer safety watchdog Rospotrebnadzor as saying on Wednesday The institute completed early-stage human trials, known as Phase II, earlier this month.
Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay Kumar Jeetendra | September 30, 2020 Mechelen, Belgium, 30 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular …
PC model disentangles puzzle behind serious aggravation in individuals with COVID-19 Kumar Jeetendra | September 29, 2020 A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation? The research shows how the molecular arrangement and arrangement of the SARS-CoV-2 spike protein–part of the virus that causes COVID-19–could be behind the inflammatory syndrome cropping up …
Why the Covid death rate actually escapes researchers Kumar Jeetendra | September 29, 2020 Global deaths from COVID-19 have reached 1 million, but experts are still struggling to figure out a key metric in the pandemic: the fatality rate – the percentage of people infected with the pathogen who die. A true mortality rate could compare deaths against the entire number of ailments, a denominator that remains unknown because …
BAT study dissects the toxicological effect of nicotine pocket items Kumar Jeetendra | September 28, 2020 New research by BAT suggests that contemporary oral goods (MOPs) revealed lower toxicity reactions in certain assays than traditional cigarettes. Scientists analyzed the toxicological impact of one of BAT’s nicotine pouch products, previously called Lyft and now called Velo, in an in vitro laboratory-based test. Velo was found to be less biologically active than cigarette …
Scientists study misleading impact in nausea therapy at the molecular level Kumar Jeetendra | September 28, 2020 The molecular bases of the placebo effect are poorly understood. A team headed by Ludwig-Maximilians-Universitaet (LMU) in Munich researcher Karin Meissner has now studied the phenomenon in the context of nausea, and identified specific proteins that correlate with its positive impact. The placebo effect seems to work wonders. In certain cases, administration of a’drug’ to …
